NCT07711821 PRIMARY-HF: Heart Failure Screening in Primary Care Using Point-of- Care
| NCT ID | NCT07711821 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Universidade do Porto |
| Condition | Heart Failure |
| Study Type | INTERVENTIONAL |
| Enrollment | 160 participants |
| Start Date | 2026-03-23 |
| Primary Completion | 2027-07 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
This trial targets 160 participants in total. It began in 2026-03-23 with a primary completion date of 2027-07.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
The goal of this clinical trial is to evaluate whether the use of NT-proBNP testing and point-of-care ultrasound (POCUS) can improve the diagnosis and management of heart failure in adults aged 50 years or older with suspected heart failure or cardiovascular risk factors in primary care settings. The main questions it aims to answer are: * Does the use of NT-proBNP and/or POCUS increase the rate of new heart failure diagnoses compared with standard care? * Does this approach support earlier initiation of guideline-directed medical therapy and improve patients' quality of life? Researchers will compare standard care alone with standard care combined with NT-proBNP testing, POCUS, or both, to assess their impact on diagnosis and management of heart failure. Participants will: * Be randomly assigned to one of four groups (standard care, NT-proBNP, POCUS, or both). * Undergo clinical evaluation for heart failure according to their assigned group. * Be followed for 12 months with periodic assessments of quality of life and treatment adherence.
Eligibility Criteria
Inclusion Criteria: * Adults aged ≥50 years * Suspected heart failure (based on signs and/or symptoms) OR * Presence of at least two cardiovascular risk factors, including: 1. Diabetes mellitus 2. Arterial hypertension 3. Estimated glomerular filtration rate (eGFR) \<60 mL/min/1.73 m² 4. Albuminuria 5. Coronary artery disease or prior myocardial infarction or coronary revascularization 6. Stroke or transient ischemic attack 7. Atrial fibrillation or flutter 8. Left ventricular hypertrophy or Q waves on electrocardiogram 9. Obesity (body mass index ≥30 kg/m²) * Ability to provide written informed consent Exclusion Criteria: * Known heart failure under active hospital-based follow-up * Terminal illness or life expectancy \<1 year * Severe comorbid conditions limiting participation or follow-up * Inability to provide informed consent
Contact & Investigator
Jonathan dos Santos, MD.
✉ jonathan.santos@ua.ptJonathan dos Santos
PRINCIPAL INVESTIGATOR
Aveiro University
Frequently Asked Questions
Who can join the NCT07711821 clinical trial?
This trial is open to participants of all sexes, aged 49 Years or older, studying Heart Failure. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT07711821 currently recruiting?
Yes, NCT07711821 is actively recruiting participants. Contact the research team at jonathan.santos@ua.pt for enrollment information.
Where is the NCT07711821 trial being conducted?
This trial is being conducted at Amadora, Portugal, Lisbon, Portugal, Lisbon, Portugal, Porto, Portugal.
Who is sponsoring the NCT07711821 clinical trial?
NCT07711821 is sponsored by Universidade do Porto. The principal investigator is Jonathan dos Santos at Aveiro University. The trial plans to enroll 160 participants.
Related Trials
Related Intelligence Guides
In-depth guides covering this condition's trials, eligibility, and what to expect.